Pliant Therapeutics, Inc.
NMS: PLRXLive Quote
About Pliant Therapeutics, Inc.
Healthcare
Biotechnology
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
📊 Fundamental Analysis
Pliant Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -61.5%, which indicates that capital utilization is currently under pressure.
At a current price of $1.28, PLRX currently sits at the 22nd percentile of its 52-week range (Range: $1.09 - $1.95).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
⚠️
Beta (Risk)
Moderate Volatility
Key Financials
Market Cap
$73.69M
Trailing P/E
--
Forward P/E
-1.05
Beta (5Y)
1.25
52W High
$1.95
52W Low
$1.09
Avg Volume
700K
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App